Drugs / piritrexim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00002914 | Jul 1997 → Jun 2001 | renal pelvis/ureter urothelial carcinoma, urethra cancer, urinary bladder cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | piritrexim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002914 ↗ |
| Known as | Bw 301u | ChEMBL registry synonym — accepted as the source's own label CHEMBL7492 ↗ |
| Known as | Piritrexima | ChEMBL registry synonym — accepted as the source's own label CHEMBL7492 ↗ |
| Known as | Piritrexime | ChEMBL registry synonym — accepted as the source's own label CHEMBL7492 ↗ |
| Known as | TCMDC-137235 | ChEMBL registry synonym — accepted as the source's own label CHEMBL7492 ↗ |
| Action | Inhibit | “Dihydrofolate reductase inhibitor” CHEMBL7492 ↗ |
| Modality | Small molecule | “This was a single-agent phase II clinical trial of the antifol piritrexim in patients with advanced transitional cell carcinoma of the bladder.” PMID 12448661 ↗ Nov 2002 |
| Route | Oral | “treated with oral piritrexim at a dose of 25 mg three times daily” PMID 12448661 ↗ Nov 2002 |
| Target | DHFR | “Dihydrofolate reductase inhibitor” CHEMBL7492 ↗ |